---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-23-000005"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2023-01-24T23:59:59+00:00"
generated_at: "2026-06-20T11:04:27.238436+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# J&J Q4 sales fall 4.4% to $23.7B; adjusted EPS rises 10.3% to $2.35; 2023 guidance issued

## Summary
- Q4 reported sales $23.7B, -4.4% YoY; operational growth ex-COVID vaccine +4.6%.
- Q4 GAAP EPS $1.33 (down 24.9%); adjusted EPS $2.35 (+10.3%).
- Full-year 2022 sales $94.9B (+1.3% reported); operational growth 6.1%.
- FY2022 GAAP EPS $6.73 (-13.8%); adjusted EPS $10.15 (+3.6%).
- 2023 guidance: adj. operational sales growth ex-COVID vaccine +4.0%; adj. EPS ~$10.50 (+3.5%).

## SEC filing metadata
- accession: 0000200406-23-000005
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2023-01-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/0000200406-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/jnj-20230124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-23-000005
- JSON: https://secwatch.observer/filing/0000200406-23-000005.json
- Plain text: https://secwatch.observer/filing/0000200406-23-000005.txt

## Key facts
- Earnings Releases
  JOHNSON & JOHNSON reported the fourth quarter ended January 1, 2023 results: revenue $23.7 Billion, EPS $1.33.
  - Period: the fourth quarter ended January 1, 2023
  - Revenue: $23.7 Billion
  - EPS: $1.33
  - Result: reported results
  source text: • 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%* • 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/0000200406-23-000005-index.htm
- Earnings Releases
  JOHNSON & JOHNSON reported 2023 results: revenue 4.0%, EPS $10.50. Guidance initiated.
  - Period: 2023
  - Revenue: 4.0%
  - EPS: $10.50
  - Guidance: initiated
  - Result: guidance update
  source text: Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/0000200406-23-000005-index.htm
- Earnings Releases
  JOHNSON & JOHNSON reported the fiscal year ended January 1, 2023 results: revenue $94.9 Billion, EPS $6.73.
  - Period: the fiscal year ended January 1, 2023
  - Revenue: $94.9 Billion
  - EPS: $6.73
  - Result: reported results
  source text: • 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%* • 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/0000200406-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.